OTC · Drug Manufacturers - Specialty & Generic

Evotec SE (EVOTF) Stock

$6.69 +0.00% OTC: EVOTF Healthcare

Evotec SE serves as a prominent global partner, offering comprehensive drug discovery and development services to both the pharmaceutical and biotechnology sectors worldwide. The company is actively involved in advancing pharmaceutical products across a diverse array of therapeutic areas.

Valuation

MetricValue
Price$6.69
Market Cap$1.19B
P/E Ratio-3.18
P/B Ratio0.88
P/S Ratio0.83
EPS (TTM)$-0.58
52-Week High$8.52
52-Week Low$4.72
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-24.55%
ROA-11.82%
ROCE-8.50%
Gross Margin11.47%
Operating Margin-13.88%
Net Margin-26.02%
Debt/Equity0.55
Current Ratio1.68

Annual Financials (USD)

Metric20212022202320242025
Revenue$618.0M$751.0M$781.0M$797.0M$788.0M
Operating Profit$41.0M$21.0M$-48.0M$-143.0M$-141.0M
Net Profit$216.0M$-176.0M$-84.0M$-196.0M$-103.0M
EPS$1.29$-0.99$-0.47$-1.11$-0.58
Op Margin6.6%2.8%-6.1%-17.9%-17.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.2B$2.3B$2.3B$1.9B$1.8B
Total Liabilities$857.0M$1.1B$1.1B$960.0M$965.0M
Cash$699.0M$415.0M$511.0M$306.0M$418.0M
Borrowings$513.0M$507.0M$626.0M$444.0M$448.0M

Latest News

Navan Selected by Evotec for Global Travel, Expense Management MT Newswires · Jul 23, 2026 Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management Business Wire · Jul 23, 2026 Health Care Roundup: Market Talk The Wall Street Journal · Jul 16, 2026 Berenberg Downgrades Evotec to Hold From Buy, Cuts Price Target to EUR3.60 From EUR9.40 MT Newswires · Jul 16, 2026 Evotec Shares Fall After TD Cowen Downgrade MT Newswires · Jul 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$122.0M$203.0M$36.0M$18.0M$-9.0M
Investing Cash Flow$-363.0M$-597.0M$-229.0M$-203.0M$94.0M
Financing Cash Flow$-5.0M$-6.0M$-13.0M$-9.0M$-1.0M
Net Cash Flow$277.0M$-284.0M$96.0M$-205.0M$148.0M
Free Cash Flow$3.0M$22.0M$-180.0M$-114.0M$-82.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.04
EV / EBITDA-15.92
FCF Yield-6.89%
Quick Ratio1.60
Interest Coverage-7.08
Return 1Y-21.44%
Return 3Y-71.37%
Return 5Y—

Ownership

Insiders Held9.97%
Institutions Held66.59%
Institutions Float Held73.96%
Institutional HolderSharesReport Date
Old Mission Capital, LLC15,4172025-09-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BIOGYBioGaia AB (publ) $11.00 +0.00% 33.70 $1.11B 3.82%
CHIZFChina Traditional Chinese Medicine Holdings Co. Limited $0.16 +0.00% -19.84 $821.34M 6.25%
CMOPFCosmo Pharmaceuticals N.V. $77.13 +2.66% -298.59 $1.32B 3.19%
GNMLFGenomma Lab Internacional, S.A.B. de C.V. $0.86 +0.00% 8.85 $840.87M 5.81%
KSPHFKissei Pharmaceutical Co., Ltd. $25.77 +0.00% 12.66 $1.07B 3.10%

About Evotec SE

Evotec SE serves as a prominent global partner, offering comprehensive drug discovery and development services to both the pharmaceutical and biotechnology sectors worldwide. The company is actively involved in advancing pharmaceutical products across a diverse array of therapeutic areas. These encompass, among others, diabetes and its related complications, fibrosis, infectious diseases, central nervous system (CNS) disorders, oncology, pain and inflammatory conditions, immunology, rare diseases, respiratory ailments, and women's health. Evotec maintains extensive collaboration agreements with numerous leading industry entities, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd., Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Founded in 1993, the company changed its name from Evotec AG to Evotec SE in April 2019 and is headquartered in Hamburg, Germany.

Evotec SE is headquartered in DE.

Evotec SE (EVOTF) stock trades at $6.69 with a market capitalization of $1.19B. The stock is valued at a price-to-earnings (P/E) ratio of -3.18, price-to-book of 0.88, price-to-sales of 0.83. Over the past 52 weeks the stock has ranged between $4.72 and $8.52, and currently trades 21.5% below its 52-week high.

On profitability, Evotec SE generates a return on equity (ROE) of -24.55%, return on capital employed of -8.50%, an operating margin of -13.88%, a net profit margin of -26.02%.

Official website: www.evotec.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides